CMRX Stock News 16.87 05/13/2014 17:09:21 Chimerix Inc (CMRX

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chimerix Inc (CMRX) 16.87 $CMRX

Chimerix Announces First Quarter 2014 Financial Results
GlobeNewswire - Fri May 09, 6:15AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the first quarter 2014.

Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis

Chimerix's Brincidofovir (CMX001) Data Accepted for Three Presentations at 27th International Conference on Antiviral Research
GlobeNewswire - Tue May 06, 6:00AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced three presentations on its investigational broad-spectrum antiviral brincidofovir (BCV, CMX001) at the 27 International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.

Chimerix to Announce First Quarter Financial Results on May 9, 2014
GlobeNewswire - Fri May 02, 7:02AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will report financial results for the first quarter ending March 31, 2014, on Friday, May 9, 2014, before the market opens. Chimerix's management team will host a live conference call and audio webcast at 8:30 a.m. ET on Friday, May 9, 2014 to discuss the Company's results and provide a business overview.

Global Influenza A Infections Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 41 Drug profiles
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wjnvgk/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Influenza A Infections - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Vertex Pharmaceuticals Incorporated - Crucell N.V. - Hemispherx Biopharma, Inc. - Amarillo Biosciences, Inc. - SIGA Technologies, Inc. - Vironova AB - CureVac GmbH - PT Bio Farma - Viroblock S.A. - Innate Therapeutics Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Immune Targeting Systems (ITS) Ltd. - Sinovac Biotech Ltd. - Microbiotix, Inc. - Alios BioPharma, Inc. - ImmuneRegen BioSciences, Inc. - Vivaldi Biosciences Inc. - Humabs BioMed SA Drug Profiles - diridavumab - interferon alfa - FP-01 - CR-8020 - TCN-032 - midodrine hydrochloride - VX-787 - Avian Flu Vaccine - RG-7745 - Influenza A H7N7 vaccine - VIS-410 - Orvax - GSK-3206641-A - GSK-3206640A - H7N9 Vaccine - Homspera - rintatolimod - interferon alfa-n3 (human leukocyte derived) - Drug For Influenza A Infections - MIS-416 - Flufirvitide-3 - Nucleozin - Small Molecule For Influenza A - ET-001 - CR-8043 - FI-6 - Pam2Cys Vaccine For more information visit http://www.researchandmarkets.com/research/wj...nfluenza_a

Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex

Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline

Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus

Chimerix Announces Appointment of M. Michelle Berrey, M.D., M.P.H. as Chief Executive Officer
GlobeNewswire - Wed Apr 09, 8:22AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of M. Michelle Berrey, M.D., M.P.H. to the position of President and Chief Executive Officer. Dr. Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests. In addition, Dr. Berrey will continue to serve as Chimerix's Chief Medical Officer.

Increased Earnings Estimates Seen for Chimerix (CMRX): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 8:20AM CDT
Stock of Chimerix looks promising, as it is seeing solid activity on the earnings estimate revision front

3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were  Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...

Chimerix Appoints Lisa Ricciardi to Board of Directors
GlobeNewswire - Tue Apr 01, 6:00AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Lisa Ricciardi to the Company's Board of Directors.

Chimerix to Present a Summary of Brincidofovir's (CMX001) Hematologic Safety at the Annual Meeting of the European Group for Blood and Marrow Transplantation
GlobeNewswire - Mon Mar 24, 3:15PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced an upcoming presentation on its investigational broad-spectrum antiviral brincidofovir (CMX001) at the 40 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) being held March 30 - April 2, 2014 in Milan, Italy.

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection
GlobeNewswire - Fri Mar 14, 7:14PM CDT
Chimerix, Inc. (Nasdaq:CMRX) today issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.

Strength Seen in Chimerix (CMRX): Stock Soars 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:04AM CDT
Chimerix, Inc. was a big mover last session, as the company saw its shares rise over 18% on the day.

Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.

Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections
GlobeNewswire - Tue Mar 11, 6:57PM CDT
Chimerix, Inc. (Nasdaq:CMRX) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients. FDA has committed to work expeditiously with Chimerix on the design of a pivotal Phase 3 study that would be a continuation of this pilot study. Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between the FDA and Chimerix regarding the need for additional clinical development to assess brincidofovir's potential in adenovirus infection. This study is expected to begin with Josh Hardy as the first patient enrolled on Wednesday, March 12, 2014.

Chimerix Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Fri Mar 07, 6:08AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the fourth quarter and full year 2013.

Chimerix's Brincidofovir (CMX001) Safety and Antiviral Data Presented at 2014 BMT Tandem Meetings
GlobeNewswire - Fri Feb 28, 10:15AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the 2014 BMT Tandem Meetings related to its investigational antiviral with broad-spectrum activity, brincidofovir (CMX001). Brincidofovir's antiviral activity against adenovirus (AdV) and its pediatric safety and tolerability data from a randomized, controlled clinical study and Chimerix's expanded access program were presented on Thursday, February 27, 2104 during the Supportive Care Oral Abstracts Session. Brincidofovir is an investigational oral nucleotide analog in Phase 3 development, currently enrolling adult hematopoietic cell transplant (HCT) recipients in the SUPPRESS trial for the prevention of cytomegalovirus infection, with secondary endpoints including clinical and virologic evidence of DNA viral infections, including AdV, BK virus and other herpes viruses such as HHV-6 and varicella zoster virus that contribute to morbidity and mortality in the first year following HCT.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Armada Moves up as Key Player in US SI Exports

Updated Category News Views 142

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 136

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 138

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 165

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Art of Taiko Drumming at Asano Taiko Factory Tour

Updated Category News Views 142

Step into the World of Taiko Drumming at Asano Have you ever experienced the powerful beats of a taiko drum? Located in Japan, Asano Taiko offers an immersive journey into the fascinating world of taiko drumming. With over 400 years of tradition behind them, Asano Taiko is renowned for its craftsmanship, making it one of the leading manufacturers of traditional Japanese...

Continue Reading
Critical Foot Care Initiative by Forté Orthopedic and Colts

Updated Category News Views 193

Critical Support for Foot Health Needs In the heart of Indiana, a remarkable initiative is transforming the lives of those in need. Forté Orthopedic Research Institute has joined forces with the Indianapolis Colts to create an event called Hearts 2 Soles. This annual event is dedicated to improving foot health among the unhoused community. People facing homelessness...

Continue Reading
Options Activity Sparks Interest in First Majestic Silver

Updated Category News Views 212

Investors Show Strong Interest in First Majestic Silver Recent developments in the options market indicate that investors are making significant bets on First Majestic Silver (NYSE: AG). This heightened activity could be a sign of underlying trends that investors should monitor closely. What We See in the Options Market The surge in options trading for AG has caught the...

Continue Reading
Projected Surge in Enterprise GenAI Spending for 2025

Updated Category News Views 174

The Future of Enterprise Investment in GenAI Enterprises are looking forward to a significant return on investment (ROI) from generative AI (GenAI) projects by 2025. Expectations predict a 50% increase in spending, as companies shift their priorities from simply boosting efficiency to enriching human expertise with advanced technologies. Key Findings from Recent Research...

Continue Reading
Liquidity Services Expands with Auction Software Purchase

Updated Category News Views 226

Liquidity Services Enhances Its Software Offerings Liquidity Services, Inc. (NASDAQ:LQDT), a prominent player in the global commerce sector, has recently made headlines with its acquisition of Auction Software, a recognized leader in auction and marketplace technology. This step is outlined as a strategic move to boost Liquidity Services’ capabilities in the Circular...

Continue Reading